Led by Jay Pathmanathan, MD, PhD

Neurophysiology, Therapeutic Neuromodulation, and Closed-Loop Treatment Safety

The NSMS National Neurophysiology & Neuromodulation Center (aNeuro™) is an advanced translational neuroscience and therapeutic technology center integrating clinical neurophysiology, electrophysiology, neural sensing, computational neuroscience, therapeutic neuromodulation, and closed-loop safety systems for next-generation precision medicine.

Led by Jay Pathmanathan, MD, PhD, aNeuro™ develops and evaluates technologies capable of continuously measuring nervous-system function, identifying clinically meaningful neurophysiologic states, delivering precisely controlled therapeutic interventions, and evaluating physiologic response in real time.

The Center establishes the scientific, clinical, and safety framework connecting neural measurement → physiologic interpretation → therapeutic decision → controlled intervention → response monitoring → safety evaluation.

aNeuro™ bridges:

• Clinical Neurophysiology

• Electrophysiology

• Neural Signal Processing

• Neurophysiologic Biomarkers

• Therapeutic Neuromodulation

• Noninvasive Brain Stimulation

• Peripheral Nerve Stimulation

• Closed-Loop Neurotechnology

• Computational Neuroscience

• Treatment Safety

• Physiologic Feedback Control

• Human Neurotechnology

Mission

To develop safe, measurable, and adaptive neurotherapeutic systems that continuously sense, interpret, modulate, and evaluate nervous-system function across clinical and home environments.

Core Clinical Programs

Clinical Neurophysiology & Electrophysiology

aNeuro™ develops quantitative approaches for measuring and interpreting electrical activity across the central and peripheral nervous systems.

Core capabilities include:

• Electroencephalography (EEG)

• Quantitative EEG

• Evoked potentials

• Electromyography (EMG)

• Nerve conduction physiology

• Neural oscillation analysis

• Time-frequency analysis

• Neural synchrony and connectivity

• Neurophysiologic state classification

• Multimodal physiologic synchronization

• Longitudinal electrophysiologic monitoring

• Neurophysiologic biomarker development

These capabilities establish objective physiological measurements for detecting neural states, monitoring disease and treatment response, and guiding precision intervention.

Neurophysiologic Biomarkers

aNeuro™ translates complex electrophysiologic signals into measurable biomarkers that can support diagnosis, patient stratification, treatment selection, and therapeutic monitoring.

Programs focus on:

• Neural oscillations

• Spectral dynamics

• Cortical excitability

• Functional connectivity

• Neural synchronization

• Evoked responses

• Autonomic-neural interactions

• Sleep neurophysiology

• State transitions

• Treatment-response signatures

• Patient-specific electrophysiologic phenotypes

• Longitudinal neural trajectories

These biomarkers provide the measurement foundation for adaptive and closed-loop therapeutic systems.

Precision Therapeutic Neuromodulation

aNeuro™ develops and evaluates therapeutic technologies designed to modulate neural activity with precisely controlled spatial, temporal, and dose parameters.

Technology areas include:

• Transcranial electrical stimulation

• tACS / tES

• tDCS

• Peripheral electrical stimulation

• Neuromuscular electrical stimulation

• Sensory and acoustic neuromodulation

• Phase-targeted stimulation

• State-dependent stimulation

• Multimodal neuromodulation

• Personalized stimulation protocols

• Adaptive dosing

• Response-guided therapy

Treatment parameters are linked to measurable physiologic targets rather than relying exclusively on fixed therapeutic protocols.

Closed-Loop Neurotherapeutics

aNeuro™ develops closed-loop systems capable of adapting therapy according to continuously measured neurophysiologic responses.

The closed-loop architecture integrates:

Sense → Detect → Interpret → Decide → Safety Check → Treat → Measure Response → Adapt

Capabilities include:

• Real-time neural sensing

• Physiologic state detection

• Patient-specific treatment models

• Adaptive stimulation timing

• Dynamic dose adjustment

• Treatment-response monitoring

• Multimodal feedback

• Personalized control algorithms

• Uncertainty-aware decision support

• Automated treatment interruption

• Clinician-supervised adaptive control

• Longitudinal therapeutic optimization

The objective is to move neuromodulation from predetermined stimulation toward physiology-guided precision therapy.

Therapeutic Treatment Safety & Guardrails

Safety is engineered into the therapeutic control architecture rather than treated solely as a downstream evaluation step.

aNeuro™ develops multilayer treatment-safety frameworks incorporating:

• Patient-specific treatment boundaries

• Modality-specific dose limits

• Stimulation amplitude limits

• Frequency and duration constraints

• Treatment eligibility rules

• Physiologic contraindication detection

• Real-time response monitoring

• Signal-quality requirements

• Artifact detection

• Confidence and uncertainty thresholds

• Treatment inhibit states

• Safe-mode transitions

• Automatic hard-stop conditions

• Clinician override

• Event logging and traceability

• Post-treatment safety monitoring

No adaptive therapeutic action proceeds without satisfying predefined physiologic, technical, and safety conditions.

Neurotechnology Verification & Safety Evaluation

aNeuro™ supports rigorous evaluation of neurotherapeutic technologies before and during human deployment.

Evaluation capabilities include:

• Electrophysiologic performance testing

• Stimulation-response characterization

• Dose-response assessment

• Human factors evaluation

• Treatment tolerance assessment

• Failure-mode analysis

• Safety boundary verification

• Closed-loop algorithm testing

• Adverse-event monitoring

• Protocol validation

• Longitudinal safety assessment

• Clinical performance evaluation

This creates an evidence pathway connecting therapeutic mechanism, engineering performance, physiologic response, and clinical safety.

Clinical Technology Platforms

aNeuro™: Integrated neurophysiology and therapeutic neuromodulation

aEEG™: Quantitative electrophysiology and continuous neural monitoring

aStim™: Precision therapeutic neuromodulation

aLoop™: Adaptive closed-loop neurotherapeutic control

aGuard™: Treatment safety architecture, physiologic guardrails, and hard-stop controls

aNeuroMap™: Patient-specific neurophysiologic phenotyping and biomarker mapping

aNeuroTwin™: Computational modeling and patient-specific neural digital twins

Neurotherapeutic Control Systems: Physiology-guided treatment selection, dosing, monitoring, and adaptation

Integrated NSMS Neurotechnology Ecosystem

aNeuro™ serves as the neurophysiology and therapeutic-safety layer connecting NSMS sensing, AI, digital engineering, digital twin, clinical, and autonomous intervention platforms.

aSensors™ → aNeuro™
Continuous electrophysiologic and multimodal physiologic sensing

aEyes™ → aNeuro™
Imaging and structural-functional information supporting neurophysiologic interpretation

aData™ ↔ aNeuro™
Standardized neurophysiologic data, clinical evidence, interoperability, and longitudinal outcomes

aTwins™ ↔ aNeuro™
Patient-specific physiologic modeling, treatment simulation, and response prediction

aVerify™ ↔ aNeuro™
Therapeutic requirements, safety architecture, traceability, integration, verification, and validation

DrRobots™ ↔ aNeuro™
Physical delivery of sensor-guided and clinician-supervised therapeutic interventions

Together, these capabilities establish an integrated neurotherapeutic pathway:

Measure → Understand → Predict → Select → Guard → Treat → Verify Response → Adapt

R&D / Clinical Domains

• Clinical Neurophysiology

• Electrophysiology

• Quantitative EEG

• Computational Neuroscience

• Neurophysiologic Biomarkers

• Neural Signal Processing

• Therapeutic Neuromodulation

• Noninvasive Brain Stimulation

• Peripheral Neuromodulation

• Closed-Loop Neurotechnology

• Precision Neurotherapeutics

• Treatment Safety

• Adaptive Therapy

• Human Neurotechnology

• Sleep Neurophysiology

• Autonomic Neurophysiology

• Neural Digital Twins

• Neurotechnology V&V

• Physiologic Feedback Control

Leadership

Jay Pathmanathan, MD, PhD
Director, NSMS National Neurophysiology & Neuromodulation Center (aNeuro™)
Neurophysiology / Therapeutic Treatment Safety Lead

Jay Pathmanathan, MD, PhD, leads NSMS neurophysiology, electrophysiology, therapeutic neuromodulation, and closed-loop treatment-safety activities.

His work focuses on connecting objective neurophysiologic measurement with precisely controlled therapeutic intervention while establishing rigorous safety boundaries for adaptive and closed-loop neurotechnologies.

Under his leadership, aNeuro™ provides the neurophysiologic and therapeutic-safety infrastructure required to translate neural signals into measurable biomarkers, controlled interventions, real-time treatment responses, and safe personalized neurotherapeutic strategies.